We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking
Read MoreHide Full Article
On Aug 17, we issued an updated research report on Omnicell, Inc. (OMCL - Free Report) . The company announced its strategy of expanding into new markets. However, a tough competitive landscape is a dampener.
Over the past six months, Omnicell’s shares have underperformed the industry it belongs to. The stock has lost 20% against the industry’s 7.5% rise.
In second-quarter 2020, Omnicell continued to see some delays in product bookings. The company noted that it is witnessing slowdown in purchasing decisions by hospitals.
It expects to see lower product bookings and revenues through the rest of 2020 compared to what management had expected prior to the COVID-19 outbreak. Additionally, the company’s ability to access hospitals in order to perform implementations of capital equipment has been delayed in some cases.
Since Omnicell is currently unable to gauge the scope, duration and impact of the pandemic and is also uncertain about the timing of global recovery and economic normalization, it could not provide full-year guidance this time as well.
Contraction of both margins in the last-reported quarter was discouraging as well. The company’s inability to provide full-year guidance this time as well raises concerns. Other headwinds in the form of a stiff competitive landscape and tough hospital spending trends continue to bother the company.
On a positive note, the company’s optimism about the gradual resumption of elective surgeries and some on-site sales activities in regions less impacted by the pandemic is encouraging. The improvement in Service and other revenues despite the pandemic-led business challenges is impressive.
Further, as a major milestone, Omnicell recently introduced fully Autonomous Pharmacy, Omnicell One, which will be available from August. Leveraging cloud-based data and predictive prescriptive analytics, Omnicell One provides real-time visibility with actionable insights and workflow optimization recommendations that will help improve clinical, financial and operational outcomes across the pharmacy supply chain.
Zacks Rank & Key Picks
The stock carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are QIAGEN N.V. (QGEN - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Hologic, Inc. (HOLX - Free Report) .
Thermo Fisher’s long-term earnings growth rate is estimated at 15%. It currently carries a Zacks Rank #2 (Buy).
Hologic’s long-term earnings growth rate is estimated at 15.5%. The company presently sports a Zacks Rank #1.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking
On Aug 17, we issued an updated research report on Omnicell, Inc. (OMCL - Free Report) . The company announced its strategy of expanding into new markets. However, a tough competitive landscape is a dampener.
Over the past six months, Omnicell’s shares have underperformed the industry it belongs to. The stock has lost 20% against the industry’s 7.5% rise.
In second-quarter 2020, Omnicell continued to see some delays in product bookings. The company noted that it is witnessing slowdown in purchasing decisions by hospitals.
It expects to see lower product bookings and revenues through the rest of 2020 compared to what management had expected prior to the COVID-19 outbreak. Additionally, the company’s ability to access hospitals in order to perform implementations of capital equipment has been delayed in some cases.
Omnicell, Inc. Price
Omnicell, Inc. price | Omnicell, Inc. Quote
Since Omnicell is currently unable to gauge the scope, duration and impact of the pandemic and is also uncertain about the timing of global recovery and economic normalization, it could not provide full-year guidance this time as well.
Contraction of both margins in the last-reported quarter was discouraging as well. The company’s inability to provide full-year guidance this time as well raises concerns. Other headwinds in the form of a stiff competitive landscape and tough hospital spending trends continue to bother the company.
On a positive note, the company’s optimism about the gradual resumption of elective surgeries and some on-site sales activities in regions less impacted by the pandemic is encouraging. The improvement in Service and other revenues despite the pandemic-led business challenges is impressive.
Further, as a major milestone, Omnicell recently introduced fully Autonomous Pharmacy, Omnicell One, which will be available from August. Leveraging cloud-based data and predictive prescriptive analytics, Omnicell One provides real-time visibility with actionable insights and workflow optimization recommendations that will help improve clinical, financial and operational outcomes across the pharmacy supply chain.
Zacks Rank & Key Picks
The stock carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are QIAGEN N.V. (QGEN - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and Hologic, Inc. (HOLX - Free Report) .
QIAGEN’s long-term earnings growth rate is estimated at 22.3%. It currently sports a Zacks Rank #1. (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 15%. It currently carries a Zacks Rank #2 (Buy).
Hologic’s long-term earnings growth rate is estimated at 15.5%. The company presently sports a Zacks Rank #1.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>